My Malignant Melanoma
Seanty's experiences with Metastatic Malignant Melanoma. Part of www.mymalignantmelanoma.com. Email us direct at help@mymalignantmelanoma.comWednesday, 23 September 2009
PLX4032/RG7204/RO5185426
Another snappy blog title...There's a new trial of the promising drug formerly known as PLX4032 or RG7204, now known as RO5185426, as Hoffmann-Roche have a collaboration agreement with the original developer (Plexxikon)
There is a phase 2 trial just started, details here. It is encouraging that this is a phase 2 trial, but they haven't published the results of the previous Phase 2 trial yet.
It's looking reasonably hopeful, as I reported back in June., and there are a couple of people on the melanoma board hoping to go on the trial.
New results for the Phase 1 extension trial are more hopeful still than the initial phase 1 trial I reported on earlier. 70% response rate (compared with about 15% for the standard treatment), one complete response (cure), and an approximate average of 30% tumour shrinkage. Other treatments have looked good at this stage, so let's not get over-excited, but looking good so far.
When viewing the response rate, it should be borne in mind that if your tumours do not have a mutation (BRAFV600E ) which is present in 50% of melanomas, you won't get the drug, so it is only perhaps twice as good as the standard treatment in terms of response rates. The manufacturer are developing a test kit for the mutation alongside the drug to screen for people it might help.
There is a phase 2 trial just started, details here. It is encouraging that this is a phase 2 trial, but they haven't published the results of the previous Phase 2 trial yet.
It's looking reasonably hopeful, as I reported back in June., and there are a couple of people on the melanoma board hoping to go on the trial.
New results for the Phase 1 extension trial are more hopeful still than the initial phase 1 trial I reported on earlier. 70% response rate (compared with about 15% for the standard treatment), one complete response (cure), and an approximate average of 30% tumour shrinkage. Other treatments have looked good at this stage, so let's not get over-excited, but looking good so far.
When viewing the response rate, it should be borne in mind that if your tumours do not have a mutation (BRAFV600E ) which is present in 50% of melanomas, you won't get the drug, so it is only perhaps twice as good as the standard treatment in terms of response rates. The manufacturer are developing a test kit for the mutation alongside the drug to screen for people it might help.
Labels: PLX4032, RG7204, RO5185426
Archives
August 2008 September 2008 October 2008 November 2008 December 2008 January 2009 February 2009 April 2009 May 2009 June 2009 July 2009 August 2009 September 2009 October 2009 November 2009 December 2009 January 2010 February 2010 March 2010
Subscribe to Posts [Atom]